Jen Herbach on Cancer Vaccines, YC, and Founder Mode

概览

This shortened episode features Jen Herbach, founder and CEO of Adventress, explaining how her company is developing cancer vaccines intended to help the immune system recognize cancer cells it previously failed to see.

The scientific discussion centers on KRAS, a driver mutation Jen says is involved in over 30% of cancers, especially lung, colon, and pancreatic cancer. Adventress is beginning with localized pancreatic cancer, with a longer-term ambition to move from treatment into prevention.

The second half shifts to founder mode: Jen describes how Brian Chesky’s talk pushed her to get much closer to the scientific work, increase accountability, and reshape the team. She also explains how YC advice on SAFEs and board control helped Adventress preserve decision-making power when investors disagreed with the company’s scientific strategy.

分段落总结

[00:00] Adventress and the Cancer Vaccine Mission

[事实] Jen Herbach is introduced as the founder and CEO of Adventress, a Winter 2023 YC company.

[事实] Jen says Adventress makes cancer vaccines, framing cancer as ultimately a failure of the immune system to recognize uncontrolled cells as foreign.

[事实] She compares the company’s approach to giving the immune system “glasses” so it can see what it previously could not see.

[推测] The episode positions Adventress as both scientifically ambitious and emotionally resonant because the hosts respond strongly to the possibility of preventing or curing deadly cancers.

[01:30] KRAS as the First Target

[事实] Jen says there is significant overlap across cancers, and Adventress’s first target is KRAS.

[事实] She describes KRAS as a driver mutation that can turn a healthy cell into a cancerous cell and lead to uncontrolled cell growth.

[事实] Jen says KRAS causes over 30% of all cancers and is mainly found in lung, colon, and pancreatic cancer.

[推测] Targeting KRAS gives Adventress a way to pursue one vaccine strategy with relevance across multiple major cancer types.

[02:27] Starting with Pancreatic Cancer, Aiming at Prevention

[事实] Adventress is first focused on treating pancreatic cancer patients with localized disease.

[事实] Jen says many localized pancreatic cancer patients eventually relapse with metastatic incurable disease.

[事实] She says the company’s long-term vision is to move into prevention, starting with a KRAS vaccine that could prevent about 30% of all cancers.

[推测] The initial treatment setting appears to be a step toward proving the platform before pursuing broader preventive use.

[03:13] Side Effects, FDA Path, and Timeline

[事实] Jen says expected side effects are minimal and comparable to infectious disease vaccines such as COVID or flu shots.

[事实] Adventress is finalizing the product it plans to bring into patients.

[事实] The company plans to submit an IND application to the FDA and dose first patients in early 2027.

[事实] Jen clarifies that the IND process turns around relatively quickly, while preparing the application package is the larger body of work.

[04:39] Jen’s Background and Co-Founder Story

[事实] Jen studied science as an undergraduate and originally thought she would go to medical school and become an oncologist.

[事实] She decided she did not want to emotionally deal with death every day, but still wanted to work on cancer therapeutics.

[事实] She later went to graduate school and business school, then spent her career in life sciences bringing novel oncology drugs to market.

[事实] Her co-founder was her college roommate and lab partner, and he did become an oncologist.

[05:45] Why YC Helped a Life Sciences Founder

[事实] Jen says YC was an incredible experience and that she has recommended it to many life sciences companies.

[事实] She says Adventress knew life sciences but did not know startups, company building, or how to tell its story.

[事实] YC helped the company learn how to talk to investors and shifted the investor dynamic so Adventress felt more in the driver’s seat.

[推测] For Adventress, YC’s value was less about scientific expertise and more about startup communication, fundraising posture, and founder judgment.

[06:36] Founder Mode and Managing the Science

[事实] The hosts connect the conversation to founder mode and Brian Chesky’s talk at a previous retreat.

[事实] Jen says the talk was timely because she had believed she should not manage day-to-day science in the lab due to her business-side background.

[事实] She says the company was moving slower than she thought it should and was also dealing with personnel issues.

[事实] After the talk, she began getting into the details, managing the team more closely, and requiring daily end-of-day standups.

[08:24] Team Accountability and Culture Change

[事实] Jen says two team members left after she increased accountability.

[事实] One team member was fine with the new approach and was able to flourish after others left.

[事实] Adventress later hired stronger people who were more on top of the work.

[事实] The company reduced the frequency of standups after the team became more productive, but kept accountability as part of the culture.

[推测] Jen’s story presents founder mode as an active operating style that can reveal who fits the company’s pace and standards.

[09:34] Reframing Micromanagement

[事实] The hosts discuss whether “micromanaging” needs a new name because it carries a negative connotation.

[事实] They distinguish between telling people exactly what to do and wanting to understand what they did each day.

[事实] Alternatives mentioned include “partnering” and “accountability partner.”

[推测] The conversation suggests that close founder involvement can be productive when it is about clarity and accountability rather than control for its own sake.

[10:33] Investor Pressure and Scientific Conviction

[事实] Jen says YC partner Serby advised Adventress to use SAFEs and say no when an investor asked for a board seat.

[事实] Jen says she initially did not understand the value of keeping investors off the board but trusted the advice.

[事实] Later, an investor questioned Adventress’s scientific strategy, and the company disagreed with the investor’s suggested approach.

[事实] Jen says Adventress listened to the feedback, evaluated it, and concluded it was not right from both a product and scientific perspective.

[推测] The absence of investor board control let Adventress reject advice it believed would undermine the product or science.

[12:27] Fallout, Board Control, and Fast Decisions

[事实] The investor who disagreed did not participate in an additional funding round.

[事实] Jen says other investors recognized and respected Adventress for standing up for what it believed in.

[事实] Adventress later made another internal decision to improve its vaccine delivery platform without needing to bring the matter to an external board.

[事实] Jen says the company’s decisions are driven by what is best for patients and what the science and data show.

[14:07] Funding Strategy and Independence

[事实] Adventress did a second seed round on SAFEs, with no priced round and no investor board members.

[事实] The company recently added an independent board member from the biotech industry who had previously worked with them as a consultant.

[事实] Jen says the independent board member was the founders’ choice, not an investor board seat.

[事实] Jen has been asking other life sciences CEOs how they retained board control, and she heard advice to prioritize board control over valuation in a next funding round.

[推测] Adventress may be willing to accept a slightly lower valuation if it helps preserve founder control through expensive clinical development.

播客点评/总结

This episode is valuable because it connects a concrete biotech company story with broader startup operating lessons. The cancer vaccine explanation is accessible, and Jen gives enough detail about KRAS, pancreatic cancer, IND timing, and vaccine side effects to make the scientific premise understandable without turning the conversation into a technical lecture.

The strongest section is the founder mode discussion. Jen gives specific examples: daily standups, team departures, improved accountability, investor disagreement, and board control. These details make the management advice feel grounded rather than abstract.

[推测] The main limitation is that the episode is short and does not deeply examine clinical risk, trial design, manufacturing, regulatory uncertainty, or competitive science. Listeners interested in biotech diligence would likely need a longer technical discussion.

[推测] This episode is best suited for founders, biotech operators, and investors interested in how scientific conviction, board structure, and founder involvement interact inside a high-stakes life sciences startup.